Asset Details
Do you wish to reserve the book?
Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
Do you wish to request the book?
Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
2010
Overview
Clopidogrel must be metabolized to an active form to be effective. Cytochrome P-450 variants resulting in slow metabolism may reduce clinical efficacy. This study in patients with acute coronary syndromes or atrial fibrillation did not confirm diminished efficacy in those with slow metabolism.
Clopidogrel, when added to aspirin, reduces the rate of major vascular events among patients with acute coronary syndromes and atrial fibrillation.
1
,
2
Recent reports suggest that certain common genetic variants, involving the hepatic cytochrome P-450 system, that are involved in the conversion of clopidogrel to its active metabolite are associated with an increased rate of recurrent cardiovascular events, implying that the benefits of clopidogrel may be attenuated in patients with these genetic variants. Specifically, in patients who are carriers of a loss-of-function
CYP2C19
allele (including the *2 and *3 alleles), the conversion of clopidogrel to its active metabolite may be . . .
Publisher
Massachusetts Medical Society
Subject
Acute Coronary Syndrome - drug therapy
/ Acute Coronary Syndrome - genetics
/ Aged
/ Aryl Hydrocarbon Hydroxylases - genetics
/ Atrial Fibrillation - drug therapy
/ Atrial Fibrillation - genetics
/ Biological and medical sciences
/ Female
/ Genotype
/ Hemorrhage - chemically induced
/ Humans
/ Male
/ Mutation
/ Platelet Aggregation Inhibitors - adverse effects
/ Platelet Aggregation Inhibitors - therapeutic use
/ Ticlopidine - adverse effects
/ Ticlopidine - analogs & derivatives
